Cochrane · systematic review · CD013649
Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis
Beverly, A, Ong, G, Kimber, C, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
7
No studies
3
Included studies
NR
No studies 3 · 30%Ungraded 0 · 0%Very low 6 · 60%Low 1 · 10%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: Tranexamic acid versus placebo
Population: people aged 18 and over undergoing vascular surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Red cell transfusions (units per participant) up to 30 days post surgery Summary of findings: Tranexamic acid vs placebo | no estimate extracted | NR | No studies |
All‐cause mortality up to 30 days Summary of findings: Tranexamic acid vs placebo | no estimate extracted | 1 study · 100 participants | Very low Downgraded: imprecision, indirectness |
Risk of receiving any allogeneic blood product (data only available for intraoperative blood product use) Summary of findings: Tranexamic acid vs placebo | RR 0.66 [0.11, 3.95] | 1 study · 100 participants | Very low Downgraded: imprecision, indirectness |
Risk of reoperation or repeat procedure for bleeding within 7 days Summary of findings: Tranexamic acid vs placebo | RR 0.33 [0.01, 7.99] | 1 study · 100 participants | Very low Downgraded: imprecision, indirectness |
Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) Summary of findings: Tranexamic acid vs placebo | RR 1.1 [0.88, 1.36] | 1 study · 1360 participants | Low Downgraded: imprecision, indirectness |
Summary of findings: Fibrin sealant vs usual care
Population: people aged 18 and over undergoing vascular surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Red cell transfusions (units per participant) up to 30 days post surgery Summary of findings: Fibrin sealant vs usual care | no estimate extracted | NR | No studies |
All‐cause mortality up to 30 days Summary of findings: Fibrin sealant vs usual care | RR 0.44 [0.11, 1.76] | 3 studies · 585 participants | Very low Downgraded: risk of bias, imprecision |
Risk of receiving any allogeneic blood product up to 30 days Summary of findings: Fibrin sealant vs usual care | no estimate extracted | NR | No studies |
Risk of reoperation or repeat procedure for bleeding within 7 days Summary of findings: Fibrin sealant vs usual care | RR 1.03 [0.31, 3.4] | 1 study · 160 participants | Very low Downgraded: risk of bias, imprecision |
Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) Summary of findings: Fibrin sealant vs usual care | RR 0.11 [0, 5.84] | 1 study · 39 participants | Very low Downgraded: risk of bias, imprecision |